The present study therefore authenticates a novel function for RRs in degrading Mnk and blocking eIF4E dependent translational initiation, and further endorses the notion that RRs are novel potential therapeutic agents for treating triple negative and Her2 overexpressing breast cancers. Here, ERBB2 is linked to breast cancer.